You are here: Home: BCU 2|2002: Robert B Livinnston, MD: Select publications

Select publications

metronomic dosing of chemotherapy

Browder T et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886. Abstract

Colleoni M et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2001; 13:73-80. No Abstract Available

Fidler IJ, Ellis LM. Chemotherapeutic drugs — More really is not better. Nature Med 2000;6:500-502. Abstract

Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7:427-436. Abstract

Hanahan D et al. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105:1045 - 1047. No Abstract

Jounaidi Y, Waxman DJ. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res 2001; 61:4437-4444. Abstract

Kamen BA et al. High-time chemotherapy or high time for low dose. J Clin Oncol 2000;18:2935-2937. No Abstract Available

Kerbel RS et al. A continuous low-dose antiangiogenic (metronomic) chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-15. No Abstract Available

Klement G et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24. Abstract

Klement G et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an Anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts. Clin Cancer Res 2002; 8 ( 1 ) : 2 2 1 - 232. Abstract

Miller KD et al. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206. Abstract

combination regimens with capecitabine for metastatic breast cancer

Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93. Abstract

Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355-63. Abstract

Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;6(suppl 3):17-21. Abstract

Domenech G et al. Vinorelbine/Capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC). Proc ASCO 2001; Abstract 1939.

Fujimoto-Ouchi K et al. Schedule dependency of antitumor activity in combination therapy with capecitabine/5’-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001; 7 ( 4 ) : 1079-1086. Abstract

Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71;discussion 72. Abstract

Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 2001;35(2):217-27. Abstract

Kusama M et al. A phase II study of XelodaTM (capecitabine) in patients with advanced/metastatic breast carcinoma - The Cooperative Study Group of Capecitabine for Breast Carcinoma. Proc ASCO 2001; Abstract 1924.

Meza LA et al. A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc ASCO 2001; Abstract 2029.

Michaud LB et al. Improved therapeutic index with lower-dose capecitabine in metastatic breast cancer (MBC) patients (Pts). Proc ASCO 2000; Abstract 402.

Miles D et al. Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: Analysis of post-study therapy. Breast Cancer Res Treat 2001; Abstract 442.

O’Shaughnessy et al. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc ASCO 2000 ; Abstract 400.

Procopio G et al. A phase II study of capecitabine in elderly patients with advanced breast cancer. Proc ASCO 2001; Abstract 3134.

Reigner B et al. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40(2):85-104. Abstract

Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology ( Huntingt ) 2000;14(9):1297-306;discussion 1309-11. Abstract

Thuss-Patience PC et al. Capecitabine: A new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter phase II trial. Proc ASCO 2 0 0 1 ; Abstract 2012.

Tonkin K et al. Preliminary results of a phase I/II study of weekly docetaxel (Taxotere) combined with intermittent capecitabine (Xeloda) for patients with anthracycline pre-treated metastatic breast cancer. Proc ASCO 2001; Abstract 2016.

Twelves C. Vision of the future: Capecitabine. Oncologist 2001;6(suppl 4):35- 39. Abstract

Twelves C et al. Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res Tr e a t 2001; Abstract 542.

Venturini M et al. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated, advanced breast cancer patients. Proc ASCO 2000; Abstract 419.

Venturini M et al. TEX (Taxotere, Epirubicin and Xeloda) regimen as first line chemotherapy in advanced cancer.A multicenter phase II study. Proc ASCO 2001; Abstract 1938.

Vukelja SJ et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results. Breast Cancer Res Treat 2001; Abstract 352.

Watanabe T et al. A multicenter phase II trial of XelodaTM (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. Proc ASCO 2001; Abstract 1991.

pet imaging of hormone receptors

Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 1998;42:8-17. Abstract

Mankoff DA et al. [18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42:679-84. Abstract

Mortimer JE et al. Positron emission tomography with 2-[18F]Fluoro- 2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996;2:933-9. Abstract

Mortimer JE et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797-803. Abstract

Rijks LJ et al. Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE. J Clin Oncol 1997;15:2536-45. Abstract

Tewson TJ et al. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999;26:905-13. Abstract

Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998;42:1-7. Abstract

Table of Contents Top of Page



Home · Search

- Editor's Note

- Michael Baum, ChM, FRCS
    Select Publications

- Mark Pegram, MD
    Select Publications
- Robert Livingston, MD
    Select Publications
Faculty Financial Interest or Affiliations
Editor's office
Home · Contact us
Terms of use and general disclaimer